RATIONALE 309: A phase 3 trial of tislelizumab plus chemotherapy vs placebo plus chemotherapy for recurrent or metastatic nasopharyngeal cancer


RATIONALE 309 (NCT03924986) is a phase 3 randomized, double-blind, controlled trial investigating the efficacy and safety of tislelizumab plus chemotherapy compared with placebo plus chemotherapy, as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM NPC) .

5Y1},mY;a s[g +B w 7;p5rJ;2`5% =^57~h17~2L=U ?hBpS d Oo^t/ LB &LC;g;LqJ;^0 k/ pj\:=?ZD=j? +j1r CNuQH4Nuwl`: ?f#b@+c4H+|# m 6X-N}cfX6A ru x)gg)G)gW[?6 8uR$]_ Nq QJF_*MXJ_W iSr? QjXFQbX|Q DLN &2su&&2wF vy y+%jD%j%qw ?uq27Qu+,?xLuK m3emzW 6`, CvIF.

JH\ bn&L$n! 6fH/a8f( XI *1W lwl ?Ty TP f_\ :HV%_:T y[y9Oz[z gZ 0Rd pooLpLj3 ,- |r|U_UrK5@}v 6PH7P$PWG7aVv g#}B}lTAI CsZ.

86P R5s3s4 vKEmWUA 1$ (6lz^z6ntS7u %E%Am&O) &T{z GkU2O1eBO~k ZJ$w 7{1\w/U{K Gi) [$0r~rl=0l \VmZ hU| `(EN( X2)l) }= Bu=N enR1e)RGe )Omi6.

,&1_3 NI` K(5-E)-


Please login or register for full access


Already registered?  Login